लोड हो रहा है...
Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration
Rosiglitazone (Rosi) is a drug in the thiazolidinedione class for treatment of Type 2 diabetes mellitus (T2DM), which binds and activates PPARγ nuclear receptor in fat cells, sensitizing them to insulin. Despite proven antidiabetic efficacy, Rosi therapy may be associated with trabecular bone loss a...
में बचाया:
| मुख्य लेखकों: | , , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
2012
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3513662/ https://ncbi.nlm.nih.gov/pubmed/23069375 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2012.09.038 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|